Phase II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer: Updated survival and time to progression data. Yuen, A., Halsey, J., Fisher, G., Advani, R., Moore, M., Saleh, M., Ritch, P., Harker, G., Ahmed, F., Jones, C., Polikoff, J., Keiser, W., Kwoh, T. J., Holmlund, J., Dorr, A., Sikic, B. AMER ASSOC CANCER RESEARCH. 2001: 3681S

View details for Web of Science ID 000172121800140